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ABSTRACT The opportunistic Gram-negative pathogen Pseudomonas aeruginosa,
known for its intrinsic and acquired antibiotic resistance, has a notorious ability to
form bioﬁlms, which often facilitate chronic infections. The evolutionary paths to an-
tibiotic resistance have mainly been investigated in planktonic cultures and are less
studied in bioﬁlms. We experimentally evolved P. aeruginosa PAO1 colony bioﬁlms
and stationary-phase planktonic cultures for seven passages in the presence of sub-
inhibitory levels (0.1 mg/liter) of ciproﬂoxacin (CIP) and performed a genotypic
(whole-bacterial population sequencing) and phenotypic assessment of the popula-
tions. We observed a higher proportion of CIP resistance in the CIP-evolved bioﬁlm
populations than in planktonic populations exposed to the same drug concentra-
tions. However, the MICs of ciproﬂoxacin were lower in CIP-resistant isolates selected
from the bioﬁlm population than the MICs of CIP-resistant isolates from the plank-
tonic cultures. We found common evolutionary trajectories between the different lin-
eages, with mutations in known CIP resistance determinants as well as growth
condition-dependent adaptations. We observed a general trend toward a reduction
in type IV-pilus-dependent motility (twitching) in CIP-evolved populations and a loss
of virulence-associated traits in the populations evolved in the absence of antibiotic.
In conclusion, our data indicate that bioﬁlms facilitate the development of low-level
mutational resistance, probably due to the lower effective drug exposure than in
planktonic cultures. These results provide a framework for the selection process of
resistant variants and the evolutionary mechanisms involved under the two different
growth conditions.
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Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen causing acuteand persistent infections. Bioﬁlm infections represent a major medical challenge
and are implicated in up to 60% of bacterial infections, which complicates diagnosis
and treatment (1). Persistent infections caused by bioﬁlm-growing P. aeruginosa strains
can either be device or tissue associated (2). Infections of catheters, intratracheal tubes
in artiﬁcially ventilated patients, and implants are examples of device-associated bio-
ﬁlms. Infections of chronic wounds, bone infections, and lung infections in patients with
cystic ﬁbrosis (CF) are examples of tissue-associated bioﬁlms (1, 2). The main reason for
the persistence of bioﬁlms implicated in infection is their multifactorial intrinsic toler-
ance toward antimicrobial agents and the immune system, which has been intensively
studied (1). Such persistence of P. aeruginosa in bioﬁlms causes a reoccurrence of the
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infection and requires repeated courses of antibiotics that may encourage the devel-
opment of antibiotic resistance.
Bioﬁlms are spatially structured heterogeneous environments due to the impaired
diffusion of nutrients and due to the consumption of oxygen by the metabolically
active superﬁcial bacterial layers (3). The colony bioﬁlm model chosen in this study was
shown to be spatially heterogeneous and able to diversify due to the concentration
gradients established within the colony (4). Zhang et al. (5) has convincingly demon-
strated that concentration gradients can strongly promote antibiotic resistance devel-
opment. Therefore, we hypothesize that the bioﬁlm environment might be supportive
of resistance development, and there is already some body of evidence suggesting that
bioﬁlm growth provides a speciﬁc niche for mutational events (6, 7). For instance,
endogenous oxidative stress in the bioﬁlm of P. aeruginosa has been shown to promote
mutagenesis via mutagenic repair of double-strand breaks in DNA (8).
The major mechanisms of intrinsic and acquired mutational resistance of P. aerugi-
nosa have been elucidated, but the evolutionary trajectories of resistance development
have been studied mainly in planktonically grown cultures (9) or in continuous cultures
where both planktonic and bioﬁlm populations were maintained (10). One of the
purposes of evolution studies is to predict resistance development, which may aid in
the design of superior treatment regimes. However, the predictive value of such
experiments depends largely on the degree to which they represent relevant in vivo
conditions (11). In particular, planktonic cultures of exponentially grown bacterial
populations experiencing homogenous environments may not represent an appropri-
ate laboratory model for chronic infections involving bacterial bioﬁlms.
P. aeruginosa infection in the cystic ﬁbrosis lung starts as a focal infection (12) and
spreads to new areas of the lung during the progression of the disease We established
in this study a bioﬁlm evolution model trying to reproduce this dynamic in which
bacteria with a history of bioﬁlm growth and exposure to antibiotics form new bioﬁlms.
In the colony bioﬁlm model used in this study, the bacteria are fed from the surface
on which they are growing and therefore can be a model for bioﬁlms associated with
soft tissue infections (13).
The ﬂuoroquinolone ciproﬂoxacin (CIP), the only antipseudomonal drug available
for oral administration, is extensively used to treat bioﬁlm infections caused by P.
aeruginosa (14). It is used together with colistin or tobramycin for the prevention of
chronic lung infections in CF patients with intermittent P. aeruginosa colonization of
their lungs and as maintenance therapy in chronically infected patients (15, 16).
However, resistance to this antibiotic is easily acquired through mutations (17). In
addition to selecting resistant mutants, ﬂuoroquinolones have been shown to promote
evolution in planktonic cells by means of different pathways involving oxidative stress,
SOS response, or direct DNA interactions (18).
Experimental evolution during exposure to inhibitory concentrations of the antibi-
otic has repeatedly shown the development of resistance to ciproﬂoxacin in P. aerugi-
nosa (19, 20). In clinical settings, however, compartments where ciproﬂoxacin does not
reach bacterial inhibitory concentrations are created, such as inside the sputum in the
conductive zones of the airways (21). In addition, ciproﬂoxacin is excreted in sweat and
present on the skin at low concentrations for long periods of time (22), with rapid
development of resistance in skin bacteria. Therefore, it is relevant to address the role
of subinhibitory concentrations of ciproﬂoxacin in the development of resistance, and
we have already published a study on the fast development of resistance in planktonic
experimental evolution (23) and in ﬂow cell bioﬁlms using a monitor for mutations in
nfxB, the negative regulator of the MexCD-OprJ efﬂux pump (24); similar ﬁndings were
reported by Macià et al. (25).
In the present study, we tested the hypothesis that the dynamics of resistance
development differs between bioﬁlms and planktonic cultures. To do this, we con-
ducted experimental evolution in both bioﬁlm and planktonic cultures exposed to a
constant subinhibitory concentration of CIP (Fig. 1). We demonstrate that a larger
CIP-resistant population evolved in bioﬁlms than in planktonic cultures. Further, we
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sequenced entire bacterial populations evolved as bioﬁlms or as batch cultures to
identify common evolutionary pathways among different lineages of the evolved
populations. While mutations in genes with similar functions were found across setups,
culture-speciﬁc variants were also identiﬁed, indicating that the mode of growth is an
important aspect of resistance development.
RESULTS
Evolution of low-level resistance occurred at a higher rate in bioﬁlms than in
planktonic cultures. Analysis of CIP resistance development in CIP-evolved P. aerugi-
nosa PAO1 populations showed that, at the last passage, the size of the resistant
subpopulations recovered from the different lineages plated on LB containing 1
mg/liter and 2 mg/liter CIP was signiﬁcantly larger for bioﬁlm-evolved populations than
for planktonic populations (Fig. 2A). As expected, the size of these resistant subpopu-
lations was also signiﬁcantly larger in CIP-evolved populations than in control popu-
lations (Fig. 2A).
The dynamic of resistance development under the two growth conditions during
the evolution experiment showed that at passages P1, P2, P5, and P6, the size of the
resistant subpopulations recovered from 1 mg/liter was larger in bioﬁlms than in
planktonic cultures (P  0.03, 0.04, 0.03, and 0.008, respectively; Fig. 2B). A signiﬁcant
increase in the resistant subpopulation occurred from ﬁrst (P0) to the last passage (P6)
in CIP-evolved bioﬁlm and planktonic populations recovered from 0.5 mg/liter CIP (P 
0.001 and 0.002, respectively). For bioﬁlms, unlike planktonic growth, the increase in
resistant population from P6 compared to P0 was also signiﬁcant for populations
recovered from 1 mg/liter CIP (P 0.004). (The percentages of resistant subpopulations
FIG 1 Setup of the experimental evolution in colony bioﬁlms and stationary-phase planktonic cultures. Top, a
colony bioﬁlm was formed on polycarbonate membrane from an overnight culture of PAO1. In the step called
passage 0 (P0), membranes containing 48-h colony bioﬁlms were transferred to fresh LB plates with either CIP or
without CIP for 48 h (CTRL). Every 48 h, the colony bioﬁlms were dispersed, and the bacterial suspension was used
to start new bioﬁlms. The bacterial suspensions of CIP bioﬁlms were used to start new bioﬁlms on plates with either
CIP or without CIP (LB). The bacterial suspensions of CTRL bioﬁlms were used to start new bioﬁlms on LB plates.
This was repeated for 6 passages (P1 to P6) with four replicates per population (A, B, C, and D). Bottom, the same
setup was used for planktonic batch cultures. A 48-h stationary culture in LB was started from an overnight culture.
From the 48-h culture, two ﬂasks were inoculated: one with 0.1 mg/liter CIP and one in LB (CTRL) (P0). From CIP
stationary cultures, every 48 h, new planktonic cultures were established in ﬂasks with CIP or without CIP (LB). From
CTRL stationary cultures, every 48 h, new planktonic cultures were established in ﬂasks with LB. This was repeated
for 6 passages (P1 to P6), with four replicates per each population (A, B, C, and D).
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recovered on 0.5 mg/liter, 1 mg/liter, and 2 mg/liter CIP during the seven passages are
shown in Table S1A to C in the supplemental material, respectively.) The ﬂuctuations in
the sizes of the resistant subpopulations during the experimental evolution, observed
especially in the planktonic cultures, might reﬂect oscillations of resistant mutants in
the bacterial population caused by competition between clones with a different ﬁtness
cost.
Interestingly, in bioﬁlms, even during evolution in the absence of CIP (control), the
size of the resistant subpopulations recovered from 0.5 mg/liter CIP increased signiﬁ-
cantly (22-fold, P  0.01) in the last passage compared to the ﬁrst passage (Table S2).
A resistant subpopulation signiﬁcantly larger than the initial population was observed
already after passage 3. The initial inoculum (single colonies used to start the evolution
experiments) was tested by population analysis for the presence of preexisting resistant
subpopulations, and no growth was detected on 0.5, 1, and 2 mg/liter CIP.
FIG 2 (A) Size of the PAO1 bioﬁlm (bioﬁlm) and planktonic (PLA) populations recovered from 0.5, 1, and
2 mg/liter CIP after evolution in the presence of CIP (0.1 mg/liter) (CIP) or in the absence of antibiotic
(CTRL). The values represent the mean (SEM) of eight lineages for each growth condition. *, the size of
the resistant population is signiﬁcantly different in CIP-evolved population compared to the CTRL (P 
0.0001); **, the size of the resistant population was signiﬁcantly higher in bioﬁlm than in planktonic-
evolved populations (P  0.008 for populations recovered from 1 mg/liter CIP and P  0.0013 for
populations recovered from 2 mg/liter CIP). (B) The development of the resistant population recovered
from 1 mg/liter CIP in CIP-evolved bioﬁlm and planktonic cultures during passages (P0 to P6). The values
represent the mean (SEM) of eight lineages for each growth condition. *, the sizes of the resistant
population in CIP-bioﬁlm populations was signiﬁcantly higher than that in CIP-planktonic populations at
passages 1, 2, 5, and 6 (P  0.0329, 0.0401, 0.0283, and 0.0084, respectively); **, the size of the resistant
population in the last passage was signiﬁcantly different (P  0.004) from the ﬁrst passage (P0). (C) The
MIC levels of ciproﬂoxacin (geometric means) for isolated colonies recovered from CIP-bioﬁlm and
planktonic cultures at P0 and P6. The MIC values of 24 independent clones for each growth condition
and passage are presented. *, the MIC level was signiﬁcantly different between the colonies isolated at
P0 and P6 in bioﬁlm (P  0.005).
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The level of resistance (MIC) of ciproﬂoxacin for selected resistant colonies from
CIP-evolved bioﬁlm populations increased signiﬁcantly during the experimental evo-
lution from passage 0 to passage 6 (P  0.005) but not signiﬁcantly for colonies from
planktonic cultures (Fig. 2C). However, clones with higher MICs of ciproﬂoxacin were
isolated at the last passage (P6) in selected resistant colonies from CIP-evolved plank-
tonic cultures compared to isolates from CIP-evolved bioﬁlm cultures (Fig. 2C). The MIC
levels of ciproﬂoxacin for individual colonies from CIP-evolved populations of the
different passages are presented in Table S3.
Enrichment of bioﬁlms with resistant subpopulations during passages in the
presence of CIP. Cells dispersed by sonication from a CIP-exposed bioﬁlm were used
to initiate new bioﬁlms in the presence of CIP or on LB (see Fig. 1 for experimental
setup). After each passage, the sizes of the new bioﬁlm populations established by
plating on CIP and LB plates were estimated and used for calculation of an enrichment
level (see Materials and Methods).
At the ﬁrst passage, the population size of new bioﬁlms formed in the presence of
0.1 mg/liter CIP (half the bioﬁlm preventive concentration) was reduced by 1 log10
compared to the bioﬁlms formed on LB. The inhibitory effect of CIP on formation of
new bioﬁlms diminished gradually during evolution and disappeared after 4 passages.
From passage 4 to passage 6, there was no signiﬁcant difference between the sizes of
the bioﬁlm populations established on CIP and LB growth media.
These results show a gradual enrichment of the CIP-evolved bioﬁlm population with
CIP-resistant bacteria during the ﬁrst three passages (Fig. 3). During batch cultures (see
Fig. 1 for experimental setup), the 0.1 mg/liter CIP concentration did not affect the size
of the 48-h stationary-phase cultures. However, this CIP concentration decreased the
size of a 24-h culture by 1 log10 due to its inhibitory effect on the growth rate (PAO1
doubling time increased from 34.5  0.5 min to 71.8  4.5 min).
Different genetic responses in evolved bioﬁlms and planktonic cultures. To
understand the genetic mechanisms underlying the evolution of antibiotic resistance
during the two modes of growth, we sequenced the bioﬁlm or planktonic populations
after evolution in the presence or absence of CIP.
The distribution of mutated genes based on the differences in the frequency (%) of
each mutation within both bioﬁlm and planktonic CIP and control (CTRL)-evolved
populations were clustered according to their function, as mentioned in the Pseudomo-
nas Genome Database (26), and these are shown in Fig. 4. The sequence coverage for
each lineage is shown in Table S4, and the list of mutations identiﬁed in the populations
compared to the reference genome of PAO1 is shown in Table S5.
We identiﬁed a signiﬁcantly (P 0.05) higher number of nonsynonymous mutations
in the CIP-evolved bioﬁlm and planktonic populations than in the CTRL bioﬁlm and
planktonic populations. A total of 53 and 37 mutations were identiﬁed in the CIP-
evolved bioﬁlm and planktonic populations, respectively. In the control populations
evolved without CIP, the numbers of nonsynonymous mutations were 21 in bioﬁlms
and 30 in planktonic evolved populations. The mutational spectrum was different in
bioﬁlms from that in planktonic cultures. The numbers of indels in CIP-evolved bioﬁlms
FIG 3 Enrichment of CIP-resistant subpopulation in CIP-evolved bioﬁlm cultures during several passages
(passages 1 to 6) in the presence of subinhibitory levels (0.1 mg/liter) of CIP. Enrichment level  1 
(log10 CFU of CIP population grown on LB plates  log10 CFU of CIP population grown on CIP plates).
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and planktonic cultures were 25 and 5, the numbers of transitions were 3 and 21, and
the numbers of transversions were 25 and 11, respectively. For control bioﬁlm and
planktonic populations, the numbers of indels were 8 and 7, the numbers of transitions
were 1 and 11, and the numbers of transversions were 12 and 12, respectively.
Statistical analysis showed that transitions were signiﬁcantly more frequent in plank-
tonic populations, while transversion and indels were signiﬁcantly more frequent in
bioﬁlm populations (chi-square, 19 and 27, respectively; P  0.001).
The CIP-evolved populations were preselected on 1 mg/liter CIP (see Materials and
Methods) to ensure that only the resistant subpopulation was assessed.
Mutations in either mexR, nfxB, or mexS, which are regulators of the MexAB-OprM,
MexCD-OprJ, and MexEF-OprN efﬂux pumps, respectively, were frequent in lineages
evolved in CIP bioﬁlms, whereas mutations in nalC and nalD (regulators of MexAB-
OprM) and CIP target genes gyrA and gyrB were exclusive to the CIP-evolved planktonic
populations (Fig. 4 and Table S5). Interestingly, although found in a small proportion of
reads in lineages C and D of the CIP-evolved bioﬁlm populations only, mutations in
PA1252 encoding a malate dehydrogenase involved in the tricarboxylic acid (TCA) cycle
were observed (Table S5). In addition, mutations in a gene encoding NADH dehydro-
genase that is also involved in the TCA cycle were only detected in two lineages, A and
B, of CIP-evolved bioﬁlm populations, with a frequency of approximately 10% (Fig. 4
and Table S5).
FIG 4 Heatmap showing mutations in in CIP and CTRL-evolved populations in both bioﬁlm and planktonic cultures. Genes are clustered according to their
function reported in the Pseudomonas Genome Database (26). The intensity of color reﬂects the frequency of mutations in each replicate population.
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In both bioﬁlm and planktonic CIP-evolved populations, common evolutionary
effects of type IV pili were identiﬁed as mutations in pil genes (Fig. 4 and Table S5).
Whereas different pil genes and different types of mutations were identiﬁed under the
two growth conditions (Table S5), these genetic changes correlated with a decreased
type IV pilus-dependent twitching motility of isolates from the CIP-evolved populations
compared to that in the control populations (Table S6).
Among genes mutated in the untreated (control) bioﬁlm populations were lasR and
prmC (Table S5). LasR is a regulator of the N-acyl-homoserine lactone quorum-sensing
system, which controls different virulence factors. The mutations in lasR in lineages B
and C (Table S5) correlated with a decreased amount of protease in isolates from these
lineages (Table S7). In lineage D, mutation in prmC encoding a posttranscriptional
regulator was observed, a deﬁciency of which has been shown to lead to a quorum-
sensing-independent reduction in virulence factors (27). In untreated planktonic pop-
ulations, various genes encoding proteins involved in ﬂagellum-dependent motility
(swimming) of P. aeruginosa were found to contain mutations (Table S5). In accordance,
a decreased swimming motility of colonies from the CTRL planktonic populations was
observed (data not shown).
DISCUSSION
Short-term evolution of P. aeruginosa PAO1 bioﬁlms and stationary batch cultures in
the presence of subinhibitory concentrations of CIP led to an increase of CIP-resistant
subpopulations under both growth conditions. By the end of the experiment, the size
of the resistant subpopulation was signiﬁcantly higher in bioﬁlms than in batch
cultures. This might be due to the better adaptive environment offered by the spatially
structured and heterogeneous bioﬁlms than the relatively more homogenous environ-
ment of a planktonic culture where all cells are subjected to the same drug concen-
tration (28).
Although the relative proportion of resistant cells was higher in CIP-evolved bioﬁlms
than in batch cultures, the MIC of ciproﬂoxacin for isolates from bioﬁlm populations
was lower than the MIC for isolates from planktonic cultures. In accordance, the genetic
analysis revealed the presence of mutations in CIP target genes gyrA and gyrB confer-
ring high levels of resistance only in CIP-evolved planktonic but not in bioﬁlm popu-
lations. For example, in lineage B of CIP-evolved planktonic populations, the gyrA C248T
mutation leading to Thr83Ile, one of the most common mutations encountered in
CIP-resistant isolates (29), was found with a frequency of 90%, and the CIP-resistant
isolates collected from this lineage had a ciproﬂoxacin MIC of 32 mg/liter (Table S3). A
possible explanation might be the higher selective pressure imposed by 0.1 mg/liter
CIP on stationary batch cultures than on bioﬁlm-embedded cells. However, it is
important to notice that we have previously shown that even at a lower selective
pressure of 0.05 mg/liter CIP, gyrAmutations causing high-level ciproﬂoxacin resistance
were selected during planktonic experimental evolution of PAO1 (23), suggesting that
the selection of different CIP resistance mechanisms depends on the bacterial mode of
growth. This is in agreement with the clinically observed high prevalence of mutations
in CIP target genes in P. aeruginosa isolates from acute infections (urinary tract
infections and wounds), which are less common in isolates from chronic bioﬁlm
infections (20). In addition, our own previous observations of antibiotic resistance levels
in P. aeruginosa CF isolates with mucoid (typical bioﬁlm phenotype) and nonmucoid
phenotypes (typical planktonic phenotype) showed that the mucoid isolates were more
sensitive than the nonmucoid counterparts (30), supporting the results obtained in this
experimental study.
The different mutational spectrum observed in bioﬁlms from that of the planktoni-
cally evolved population is in accordance with recent studies showing the role played
by the environmental conditions for the mutational landscape (31, 32). The association
of transversions and indels with the bioﬁlm mode of growth might be due to the
bioﬁlm-related stress-induced mutagenesis.
Common adaptations toward mutations in genes involved in the regulation of
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multidrug efﬂux pumps mexR (MexAB-OprM), nfxB (MexCD-OprJ), and mexS (MexEF-
OprN), with all of them accommodating CIP as the substrate, were observed in
CIP-evolved bioﬁlm populations. Mutations in these genes were found in several
lineages of the CIP-evolved bioﬁlm populations and conferred a lower level of CIP
resistance than the gyrase mutations. For example, in lineage A of the CIP-evolved
bioﬁlm populations, the mexS G141T leading to Trp47Cys had reached ﬁxation, and the
CIP-resistant isolates collected from this lineage had a CIP MIC of 2 to 4 mg/liter (Table
S3). This is in accordance with previously published resistance mechanisms that were
found to be selected in PAO1 ﬂow cell bioﬁlms exposed to CIP in pharmacokinetic/
pharmacodynamic (PK/PD)-adjusted doses (25). It has previously been shown for P.
aeruginosa planktonic cultures that resistant subpopulations selected at low CIP con-
centrations are associated with the overexpression of efﬂux pumps, while high CIP
concentrations lead to mutations in gyrase and topoisomerase IV (33). Mutations in
genes involved in the regulation of MexAB-OprM and MexCD-OprD were also present
in some lineages of the planktonic populations, though different types of mutations
were identiﬁed under the two growth conditions (Table S5). Mutations in the known
regulators nalD and nalC of the MexAB-OprM efﬂux pump, as well as in PA3228, a
recently described transcriptional regulator of antibiotic resistance in P. aeruginosa (34),
were present only in the CIP-evolved planktonic populations. Interestingly, many of
these regulators of multidrug efﬂux pumps were identiﬁed as pathoadaptive genes for
P. aeruginosa evolution in the CF lungs (35), suggesting that antibiotic stress is one of
the main drivers of evolution in bioﬁlms in vivo.
A common selection against type IV pili, involved in surface attachment/adhesion,
cell-cell aggregation, bioﬁlm formation, virulence, and twitching motility of P. aerugi-
nosa (36), was also observed in lineages of CIP-evolved planktonic and bioﬁlm popu-
lations as mutations in different pil genes were identiﬁed. Type IV pili are among the P.
aeruginosa surface molecules that also function as phage receptors for Pf4 prophages
of PAO1. These prophages were shown to be activated during bioﬁlm growth and CIP
treatment (37). The presence of the ﬁlamentous bacteriophage Pf4 in the matrix of the
colony bioﬁlm model has been described previously (38). In addition, phage-driven
mutations in pil genes have also been described in PAO1 ﬂow cell bioﬁlm populations
after 7 days of evolution (39). Although we did not investigate the presence of active
phages in this study, we suggest that protection against infection with Pf4 is a possible
explanation for the differential mutation pattern of these genes in the CIP-treated
samples.
In the control planktonic populations, mutations in swimming motility genes (ﬂi,
ﬂagellar assembly) were observed. In P. aeruginosa, swimming motility is driven by a
single unipolar ﬂagellum which in PAO1 is dependent on 41 genes encoding structural/
assembly and regulatory components of the ﬂagellar organelle (40). In accordance,
phenotypic characterization of P. aeruginosa populations during planktonic experimen-
tal evolution showed a decrease in the swimming motility of the populations (41), and
this was also conﬁrmed in the present study (data not shown). This suggests that during
evolution under conditions of good oxygenation and sufﬁcient nutrition, swimming
motility is probably an energy-expensive property that is easily lost.
In bioﬁlm, but not planktonic populations, a small resistant subpopulation (85 
104%) developed during evolution in the absence of CIP-selective pressure that might
be explained by stress responses related to the bioﬁlm growth (42). In accordance with
this ﬁnding, the development of antibiotic resistance in bioﬁlms in the absence of
antibiotics has been previously reported (43). As the control populations were not
enriched for CIP-resistant phenotypes before sequencing, there might have been
genetic alterations that we did not detect at the applied sequencing depths.
In the nontreated bioﬁlm population, a common evolutionary path toward the loss
of virulence factors was observed. Mutations in the regulatory gene of the N-acyl-
homoserine lactone quorum-sensing system (lasR) were identiﬁed in a high percentage
of reads (more than 90% of reads) in two different lineages and correlated with a
reduced production of proteases in isolates from these two lineages (Table S6). A loss
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of virulence traits in in vitro PAO1 evolution has been reported previously in planktonic
cultures (41), showing that the occurrence of this phenotype in evolutionary studies is
independent of in vivo factors, e.g., immune selection. Intriguingly, mutations in the
quorum-sensing system were not present in the CIP-evolved bioﬁlm populations,
indicating a selection for the maintenance of quorum-sensing-regulated factors under
evolution at subinhibitory concentrations of CIP. In accordance, we have previously
observed increased levels of quorum-sensing molecules in planktonic evolved popu-
lations in the presence of 0.05 mg/liter CIP compared to the controls (41). One
explanation for these observations could be the protection conferred by QS-regulated
catalases and superoxide-dismutases against antibiotic-related oxidative stress (44), as
we have shown increased production of reactive oxygen species in P. aeruginosa
bioﬁlms exposed to ciproﬂoxacin (45). Kohanski et al. showed that hydroxyl radicals
resulted from the activation of the bacterial TCA cycle are involved in the bactericidal
effect of quinolones, and mutants in enzymes involved in the TCA cycle were protected
against antibiotic killing (46). In accordance with the metabolic changes caused by
exposure to CIP, we found mutations in PA1252 encoding L-malate dehydrogenase, an
enzyme of the TCA cycle, in two independent CIP-evolved bioﬁlm populations, prob-
ably as a protective mechanism against hydroxyl radical formation and antibiotic killing.
Additionally, two mutations in NADH dehydrogenase were only observed in CIP-
evolved bioﬁlm populations. A mutation in NADH dehydrogenase is involved in the
inhibition of malate dehydrogenase in the TCA cycle (47). It has been shown previously
that P. aeruginosa mutants in NADH dehydrogenase are more tolerant to tobramycin
(48).
Although we may claim that the evolution of antibiotic resistance studied in an in
vitro bioﬁlm model is more representative of the development of resistance during
chronic infections, there are several limitations of our study. Among them, the use of
a laboratory growth medium and the exposure to constant subinhibitory concentration
of CIP are clear simpliﬁcations not reﬂected in the nutrient and pharmacokinetic
ﬂuctuations encountered by the bioﬁlms in vivo.
The survival of resistant mutants in a bacterial population depends also on the
ﬁtness cost of various mutations (49). An accumulation of compensatory mutations
improving the adaptive capacity of the resistant mutants to a particular environment
has been observed during evolution in CF sputum medium (19). Our ﬁndings suggest
that isolates with a history of bioﬁlm growth and environmental exposure to subin-
hibitory concentrations of antibiotics are more likely to contain mutations causing
low-level resistance, which might accelerate the in vivo stepwise development of
resistance. From a clinical perspective, this underlines the importance of using combi-
nations of antibiotics to treat bioﬁlm infections in order to prevent mutational resis-
tance and the beneﬁt of achieving high antibiotic concentrations at the infection site
in order to prevent the seeding of new bioﬁlms by resistant mutants detached from
existing bioﬁlms. For future studies, temporal sequencing and competition studies of
the CIP-resistant isolates selected during experimental evolution would deepen our
understanding of the quantitative dynamics of resistance development under different
conditions.
MATERIALS AND METHODS
Bacterial strains, media, and antibiotics. P. aeruginosa strain PAO1 (planktonic MIC ciproﬂoxacin,
0.094 mg/liter) was used to test the development of antibiotic resistance during experimental evolution
in the colony bioﬁlm model (4) and in planktonic batch cultures. Both bioﬁlms and planktonic cultures
were grown in Luria-Bertani (LB) medium and exposed to CIP (ciproﬂoxacin hydrochloride; Bayer;
Germany), as described below. The MIC for a 48-h stationary PAO1 culture was 0.2 mg/liter, the minimal
bioﬁlm inhibitory concentration was 0.5 mg/liter, and the bioﬁlm preventive concentration was 0.2
mg/liter (methods are described in the supplemental material).
Experimental evolution of colony bioﬁlm cultures. A single colony of P. aeruginosa PAO1 was used
to inoculate LB for an overnight culture, incubated aerobically at 37°C. Five microliters of the diluted
overnight culture containing approximately 106 cells (optical density at 600 nm [OD600] adjusted to
0.005) was spot-inoculated on the top of polycarbonate membrane ﬁlters (Whatman Nuclepore track-
etched membranes, 25-mm diameter, 0.2-m pore size) and incubated at 37°C to form 48-h colony
bioﬁlms on LB plates. Membranes containing 48-h colony bioﬁlms were transferred to fresh LB plates
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with either 0.1 mg/liter CIP (1/5 minimal bioﬁlm inhibitory concentrations) (CIP) or without CIP for 48 h
(CTRL) (passage 0 consisted of a 4-day-old bioﬁlm, 2 days on LB, followed by 2 days on LB with CIP). Every
48 h, the CIP and CTRL membranes were transferred to 10-ml tubes with saline, and bioﬁlms were
dispersed by vortexing (2 min) and sonication (10 min). After adjusting the OD600 to 0.005, 5 l of the
bacterial suspension of CTRL bioﬁlms was used to start new bioﬁlms on LB plates without antibiotics, and
5 l of the bacterial suspensions of CIP bioﬁlms was used to start new bioﬁlms on plates with either 0.1
mg/liter CIP or on LB (Fig. 1).
A total of seven exposures (6 passages) to CIP with 4 independent lineages per experiment were
performed in duplicate (a total of 8 lineages). Different single colonies were used to start each
experiment. After each 48 h, the CFU counts for each bioﬁlm populations were measured, and the
disrupted bioﬁlm populations were kept in 20% glycerol at 80°C until further analysis. The enrichment
level of bacterial populations with CIP resistance variants able to form bioﬁlm in the presence of CIP was
calculated by using the following equation: enrichment level  1  (log10 CFU of CIP population grown
on LB plates  log10 CFU of CIP population grown on CIP plates).
Experimental evolution of planktonic cultures. Planktonic experiments were conducted with the
same experimental design as implemented with bioﬁlm cultures, achieving similar numbers of bacterial
generations in the two modes of growth. Brieﬂy, 5 l of an overnight culture (OD600 adjusted to 0.005)
started from a single colony of PAO1 (the same single colony used to start the evolution experiment in
bioﬁlms) was used to inoculate 10 ml LB medium and incubated for 48 h with shaking on an orbital
shaker (180 rpm) at 37°C. From the 48-h culture, two ﬂasks were inoculated, one with 0.1 mg/liter CIP
(CIP) and one in LB (CTRL) and this was called passage 0 (P0). From CIP stationary cultures, every 48 h,
new planktonic cultures were established by passing a volume of 5 l in ﬂasks with CIP or without CIP
(LB). From CTRL stationary cultures, every 48 h, new planktonic cultures were established in ﬂasks with
LB. This was repeated for 6 passages (P1 to P6) (Fig. 1). The effect of CIP 0.1 mg/liter on the growth rate
of PAO1 was determined by OD600 measurements during 8 h of culture in LB in the presence or absence
of 0.1 mg/liter CIP, in triplicate.
Population analysis. Bacterial populations (100 l of different dilutions) obtained after sonication
and vortexing of membranes containing colony bioﬁlms or of planktonic cultures from each passage and
treatment group were plated on LB plates to estimate the size of the bacterial population and on LB
plates containing 0.5, 1, and 2 mg/liter CIP and incubated for 48 h to estimate the size of the resistant
subpopulations (growing on CIP concentrations higher than the MIC of the strain PAO1). The size of the
resistant population was expressed as a percentage of the total bacterial population and was calculated
by dividing the CFU per milliliter on CIP by the CFU per milliliter on LB and multiplying by 100.
Three colonies were selected from the plates with the highest CIP concentrations allowing growth.
These were passed twice in antibiotic-free medium, and the MIC of CIP was determined by performing
an Etest (bioMérieux), according to the manufacturer’s instructions.
Genome sequencing of evolved bacterial populations. The CIP-evolved populations (after 7
passages in the presence of 0.1 mg/liter CIP) from four bioﬁlm lineages and four planktonic lineages were
grown on LB plates containing 1 mg/liter CIP for 48 h (four different lineages/condition). The CTRL-
evolved populations (after seven passages in the absence of CIP) from bioﬁlm and planktonic cultures
were grown on LB plates. All colonies for each population were collected in 3 ml saline (0.9% NaCl) for
genomic DNA extraction using the Gentra Puregene yeast/bacteria DNA puriﬁcation kit. The DNA was
prepared for sequencing using the Illumina TruSeq DNA Nano kit and sequenced on an Illumina MiSeq
platform, yielding approximately 5 million reads per sample corresponding to a coverage depth of
approximately 120 (Table S3). Sequencing reads were mapped to the reference genome of P.
aeruginosa PAO1 (GenBank accession no. NC_002516), and single- and multiple-nucleotide variants (SNVs
and MNVs, respectively) were called using CLC Genomics Workbench (Qiagen). R (version 3.2.5) was used
for further statistical analysis of the mutations detected in each population. Brieﬂy, all mutations
occurring in 10% of the reads at any given position were included in the analysis and ﬁltered based
on their presence in the CTRL populations (those evolved without CIP). Only mutations in annotated
coding regions were included in the analysis.
Statistical analysis. Graphs and statistical analysis were done using GraphPad Prism 7 software and
R (version 3.2.5). We conducted a D’Agostino-Pearson omnibus test to check for normal distribution of
the data. Student’s t test was used for comparisons among populations with normal distribution and
Mann-Whitney test when the data failed to pass the normality test. A chi-square test was conducted to
test the distribution of the different types of mutations between bacterial populations. The differences
were considered signiﬁcant when the P value was 0.05.
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